Treatment of Pulmonary Arterial Hypertension Due to Scleroderma: Challenges for the Future

Rheumatic Disease Clinics of North America

Volumn 34, Issue 1, 2008, Pages 191-197

  Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENOMEDULLIN; BERAPROST; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ILOPROST; IMATINIB; PROSTACYCLIN; RHO KINASE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADD ON THERAPY; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG TARGETING; EARLY DIAGNOSIS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SINGLE DRUG DOSE; TREATMENT RESPONSE;

BIOSYNTHETIC PATHWAYS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOLOGIC FACTORS; NEOVASCULARIZATION, PATHOLOGIC; SCLERODERMA, SYSTEMIC;

EID: 40149094466     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.11.003     Document Type: Review

References (42)

1. Kawut S.M., Taichman D.B., Archer-Chicko C.L., et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 (2003) 344-350
2. MacGregor A.J., Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 40 (2001) 453-459
3. Fagan K.A., and Badesch D.B. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 45 3 (2002) 225-234
4. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl (2004) 14S-34S
5. de Groote P., Gressin V., Hachulla E., et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 67 (2008) 31-36
6. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
7. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26 (2000) 81-84
8. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR2, a receptor member of the TGF-beta family. J Med Genet 37 (2000) 741-745
9. Nakerakanti S.S., Kapanadze B., Yamasaki M., et al. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 281 (2006) 25259-25269
10. Fonseca C., Renzoni E., Sestini P., et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 54 (2006) 3034-3042
11. Yuan J.X., and Rubin L.J. Pathogenesis of pulmonary artery hypertension: need for multiple hits. Circulation 111 (2005) 534-538
12. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
13. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
14. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98 (1998) 400-406
15. Mandegar M., Remillard C.V., and Yuan J.X. Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis 45 (2002) 81-114
16. Denton C. Therapeutic targets in systemic sclerosis. Arthritis Res Ther 9 Suppl 2 (2007) S6
17. Eddhaibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108 (2001) 1141-1150
18. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
19. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
20. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
21. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
22. Galiè N., Ghofrani H.N., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
23. Fanburg B.L., and Lee S.L. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272 (1997) L795-L806
24. Long L., MacLean M.R., Jeffery T.K., et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98 (2006) 818-827
25. Said S.I. Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 291 (2006) 547-558
26. Petkov V., Mosgeoller W., Ziesche, et al. Vasoactive intestinal polypeptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
27. Oka M., Homma N., Taraseviciene-Stewart L., et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100 (2007) 923-929
28. Abe K., Shimokawa H., Morikawa K., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94 (2004) 385-393
29. Yeager M.E., Halley G.R., Golpon H.A., et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88 (2001) 2-11
30. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821
31. Ghofrani H.A., Seeger W., and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353 (2005) 1412-1413
32. Nagaya N., and Kangawa K. Adrenomedullin in the treatment of pulmonary hypertension. Peptides 25 (2004) 2013-2018
33. von der Hardt K., Kandler M.A., Chada M., et al. Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure. Eur Respir J 24 (2004) 615-623
34. Nagayaa N., Nishikimib T., Uematsua M., et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 84 (2000) 653-658
35. Zhao Y.D., Courtman D.W., Deng Y., et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 (2005) 442-450
36. Wang X.X., Zhang F.R., Shang Y.P., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49 (2007) 1566-1571
37. Indolfi C., Cioppa A., Stabile E., et al. Effects of hydroxymethylglutaryl coenzyme-A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 35 (2000) 214-221
38. Nishimura T., Faul J.L., Berry G.J., et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166 (2002) 1403-1408
39. Nishimura T., Vaszar L.T., Faul J.L., et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis in neointimal smooth muscle. Circulation 108 (2003) 1640-1645
40. McLaughlin V.V., Oudiz R.J., Frost A., et al. A randomized, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
41. Simonneau G., Rubin L.J., Galie N., et al. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension. [abstract]. Am J Respir Crit Care Med 175 (2007) A300
42. Voelkel N.F., Quaife R.A., Leinwand L.A., et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114 (2006) 1883-1891